All News
Drug Safety Differences with New Novel Therapies in RA
Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.
Read Article
Older Lupus Patients Need Follow-Up After Hospital Discharge
MedPage Today
Medicare beneficiaries 65 and older with lupus faced dramatically higher mortality when they received no follow-up care during the month after a hospital stay, researchers found.
Read Article
Retrospective study of 64 gout pts having orthopedic surgery - perioperative flares more likely with Incr SUA, DM, tophi and diuretics. In 12 mos following surgery, recurrent gout more if ^SUA (45% vs 11%) & those w/ topic ((RR = 4.8; P = 0.029) https://t.co/iMDSWnb5Dv https://t.co/ZwUKBkZbSL
Links:
Dr. John Cush RheumNow ( View Tweet)
NOVESA trial ziritaxestat (an autotaxin inhibitor) in 33 early diffuse systemic sclerosis pts. After 24 wks, ziritaxestat showed signif reduction in mRSS (–8.9 vs. –6.0 PBO; P=0.04). It was well tolerated & showed biologic effect w/ reduced LPA C18:2 https://t.co/GKC2TKOQhE https://t.co/AUaminOyiH
Links:
Dr. John Cush RheumNow ( View Tweet)
Large-scale genome-wide association study of R A (276,020 samples in 5 ancestral grps) identified 124 loci (P < 5 × 10−8), 34 being novel. Candidate genes showed essential roles for TNIP2, TNFRSF11A, WISP1 in RA. https://t.co/jk1ePlen5l https://t.co/aSIZYJ9oky
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of HBV reactivation in HBsAg−/HBcAb+ RA ( 26 studies 2252 pts) Rx w/
b/tsDMARDs. Pooled HBV reactivation = 2%. Reactivation higher w/ RTX (esp if HBsAb−)
RTX 9% (p .03)
ABA 6%
JAKi 1%
IL‐6i 0%
TNFi 0%
Safe to use TNFi, JAKi, IL6 mAbs
https://t.co/YCIISZTigX https://t.co/RmzAObr6w1
Links:
Dr. John Cush RheumNow ( View Tweet)
Subanalysis of DISCOVER-1 RCT w/ IL-23 inhibitor guselkumab, showed similar response in TNFi-naive (n 118) & TNFi-experienced (263) Rx w/ guselkumab Q4W (76% & 68%) or Q8W (61% & 58%), yet skin responses (PASI90) were better in TNFi-naive Rx PsA pts.
https://t.co/tsKuLZw7dQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Will we see you there?
https://t.co/hQOwBQtOny https://t.co/wwNF0gjpEj
Links:
Dr. John Cush RheumNow ( View Tweet)
Without DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis
The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of DMARDs, according to Seminars in Arthroplasty.
https://t.co/iGAQaa7Ppc https://t.co/AbteC427wI
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Methotrexate Increase Skin Cancer Risk?
A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses.
https://t.co/tNNpFC6LiN https://t.co/x8Fuus2r8O
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE.
https://t.co/0g2VM6TJt6 https://t.co/f6wylPc5ep
Links:
Dr. John Cush RheumNow ( View Tweet)
Recent Cochrane review of Vit D, Calcium and OP shows no evidence to support the isolated or combined use of calcium & vit D in premenopausal women to improve BMD (hip or spine) or results in the prevention of fractures (vertebral and non‐vertebral). https://t.co/ZbXuPAJcGv https://t.co/pai4gmMKoI
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study of Taiwan Health Insurance Database looked at risk of #SLE in pts w/ Hashimoto’s thyroiditis (HT). Compared 15K HTvs 31K controls. SLE was incr in HT pts (IRR 3.58; p < 0.01). Several sensitivity analyses aHR 4.35 to 5.11 https://t.co/QaWEN4Chw9 https://t.co/bD8zrCJEXY
Links:
Dr. John Cush RheumNow ( View Tweet)
NLRP12 is a negative regulator of innate immune activation and type I interferon production. SLE PBMCs have low levels NLRP12 (inverse correl w/ IFNa & Hi Dz activity. NLRP12 knockouts or deficiency Incr autoAbs, inflammation & renal damage https://t.co/VICAqKmK9r https://t.co/MxqcNzh6BQ
Links:
Dr. John Cush RheumNow ( View Tweet)
New 5 Peptide Autoantibody Panel Complements RA Diagnosis
Antibodies to peptides not currently used for rheumatoid arthritis (RA) diagnosis helped identify patients with untreated early disease that conventional biomarkers missed, researchers said.
https://t.co/lOZvXBp7c1 https://t.co/6JVpeOyGYu
Links:
Dr. John Cush RheumNow ( View Tweet)
Systemic Sclerosis cohort study of 506 SSc pts with saw 5.3 with Degos-like lesions (89% in fingers). Degos lesions more assoc w/ diffuseSSc & acro-osteolysis, digital ulcers, and calcinosis (but not renal crisis, ILD, or pulmonary HTN
https://t.co/eCumzZvEmO https://t.co/B41NLt4RYF
Links:
Dr. John Cush RheumNow ( View Tweet)
Multicenter study of 80 AOSD & 60 controls used to develop AOSD criteria:
- 3 pts rash
- 3pts fever ≥ 39C
- 2 pts pharyngitis
- 2 pts arthritis
- 2 pts NLR ≥ 4
- 1 pt glycosyl ferritin ≤ 20%
7 pts = Dx (sens 92.5%) vs Yamaguchi(79%), Fautrel (76%) https://t.co/UvtSABRs8s https://t.co/LzqWdyaj8h
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read, solid review of Diagnosis and management of autoimmune hepatitis from BMJ https://t.co/mc1ozL6CG8 https://t.co/xQkX7WpETv
Links:
Dr. John Cush RheumNow ( View Tweet)
Pregnancy & RA: metanalysis of 9 studies, 12K RA pts met vs 10 million controls. RA preg have more maternal complications (C sect OR 1.55; preeclampsia OR, 1.6; preterm OR, 1.8) & neonatal probs (low gestat wt, ICU OR 1.34, & stillbirths OR, 1.99). https://t.co/1hA0zGsDtk https://t.co/awaV07GbEv
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! RheumNow Live is unlike any meeting you've ever attended.
Here's why:
-Inspired Education
-The Audience Matters
- A meeting designed to change your mind and practice.
https://t.co/wWjsjWATdv https://t.co/Rd7O3Yhpw3
Links:
Dr. John Cush RheumNow ( View Tweet)
